Berlin names Health Innovation Quarter Berlin-Mitte the new place of the future
Charité and Bayer are initiating the new ecosystem, which links research, industry and start-ups over five kilometers.
Advertisement
A new place is being created in the heart of Berlin where science, industry and start-ups are working together on the health innovations of tomorrow: the new future location "Health Innovation Quarter Berlin-Mitte". With Charité and Bayer as initiators, a powerful innovation network is coming together that links research, development and clinical application more closely and makes the transfer of medical innovations into practice more successful.
Senator for Economic Affairs Franziska Giffey has officially named the Health Innovation Quarter Berlin-Mitte as the newest future location. The location has thus been included in the network of innovative science and technology locations in the capital. With the Health Innovation Quarter Berlin-Mitte, there are now twelve future locations in Berlin.
This new future location stretches for around five kilometers from the Charité-Mitte campus along the Spree Canal and Humboldthafen, via the Bayer site between Nordhafen and Müllerstrasse, to the Charité Campus Virchow-Klinikum. This area is already an internationally visible focus for health innovations and will offer companies and spin-offs from all over the world ideal conditions to quickly develop and test their ideas and turn them into marketable therapies.
Franziska Giffey, Mayor and Senator for Economics, Energy and Public Enterprises: "Berlin's future locations represent what our capital city economy is all about: Innovative strength, collaboration and diversity. This is where business, science and urban society come together to develop solutions for the future. The Health Innovation Quarter Berlin-Mitte demonstrates the successful close integration of cutting-edge research and industry and is an important beacon of the healthcare industry. As the state of Berlin, we are working together with the federal government to promote the networking of our future-oriented locations. The addition of the twelfth Health Innovation Quarter is a strong signal for the future viability of our city."
The new future location "Health Innovation Quarter Berlin-Mitte" sets standards for the sustainable strengthening of Berlin as a business location. With a clear focus on health innovations, a powerful ecosystem is being created here that covers the entire value chain. The close integration of research, development, production and clinical application, in particular through the cooperation between Charité - Universitätsmedizin Berlin and Bayer AG, symbolizes the ideal combination of science, research and business. In addition, the internationally renowned future location creates the basis for stronger networking between all players and for social dialog on scientific progress in the healthcare sector.
"The close partnership between Charité and Bayer AG is an expression of the effective combination of university medicine and industrial innovation. Together, we are not only strengthening the development of new therapies, but also making an important contribution to the economic dynamism and international competitiveness of Berlin as a location," says Astrid Lurati, Charité's Chief Financial and Infrastructure Officer.
The innovation hub aims to position Berlin as a leading location for prevention, personalized medicine and novel treatment methods, such as gene and cell-based therapies. It will become a hub for first-class research institutions and up-and-coming start-ups in the field of modern medicine and science.
"With the designation as a Zukunftsort, we are strengthening the visibility of the emerging ecosystem for health innovations in Berlin-Mitte. The aim of the players is to accelerate the development of new therapies and technologies locally. We are convinced that the emerging infrastructure and the networking of companies and research institutions will form the basis for future innovations. The designation as Berlin's twelfth Zukunftsort is a strong signal for all those involved of what has already been achieved and an additional incentive for future success," says Stefan Oelrich, member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.